Clinical Trial Update: Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating talquetamab in combination with iberdomide and dexamethasone for relapsed or refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Talquetamab (talquetamab)
• iberdomide (iberdomide)

Snippet

Sponsor: Alfred Chung, MD | Conditions: Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING